COVID-19 transmission, current treatment, and future therapeutic strategies
VS Salian, JA Wright, PT Vedell, S Nair… - Molecular …, 2021 - ACS Publications
At the stroke of the New Year 2020, COVID-19, a zoonotic disease that would turn into a
global pandemic, was identified in the Chinese city of Wuhan. Although unique in its …
global pandemic, was identified in the Chinese city of Wuhan. Although unique in its …
Interleukin-6 cytokine: An overview of the immune regulation, immune dysregulation, and therapeutic approach
Several studies have shown that interleukin 6 (IL-6) is a multifunctional cytokine with both
pro-inflammatory and anti-inflammatory activity, depending on the immune response …
pro-inflammatory and anti-inflammatory activity, depending on the immune response …
[HTML][HTML] Recent advances in management of COVID-19: A review
Abstract The coronavirus disease 2019 (COVID-19) pandemic caused and is still causing
significant mortality and economic consequences all over the globe. As of today, there are …
significant mortality and economic consequences all over the globe. As of today, there are …
[HTML][HTML] Therapeutics for COVID-19 and post COVID-19 complications: An update
Since its inception in late December 2020 in China, novel coronavirus has affected the
global socio-economic aspect. Currently, the world is seeking safe and effective treatment …
global socio-economic aspect. Currently, the world is seeking safe and effective treatment …
Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials
Abstract Purpose Interleukin-6 (IL-6) levels discriminate between patients with mild and
severe COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a …
severe COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a …
A systematic review of the global intervention for SARS-CoV-2 combating: from drugs repurposing to molnupiravir approval
NA Ashour, A Abo Elmaaty, AA Sarhan… - Drug design …, 2023 - Taylor & Francis
The rising outbreak of SARS-CoV-2 continues to unfold all over the world. The development
of novel effective antiviral drugs to fight against SARS-CoV-2 is a time cost. As a result, some …
of novel effective antiviral drugs to fight against SARS-CoV-2 is a time cost. As a result, some …
[HTML][HTML] The find of COVID-19 vaccine: Challenges and opportunities
Severe acute respiratory syndrome coronavirus (SARS-CoV-2), a novel corona virus,
causing COVID-19 with Flu-like symptoms is the first alarming pandemic of the third …
causing COVID-19 with Flu-like symptoms is the first alarming pandemic of the third …
Overview of COVID-19 disease: virology, epidemiology, prevention diagnosis, treatment, and vaccines
I Salahshoori, N Mobaraki-Asl, A Seyfaee… - Biologics, 2021 - mdpi.com
Coronaviruses belong to the “Coronaviridae family”, which causes various diseases, from
the common cold to SARS and MERS. The coronavirus is naturally prevalent in mammals …
the common cold to SARS and MERS. The coronavirus is naturally prevalent in mammals …
[HTML][HTML] A critical analysis of SARS-CoV-2 (COVID-19) complexities, emerging variants, and therapeutic interventions and vaccination strategies
Coronavirus is a family of viruses that can cause diseases such as the common cold, severe
acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS). The …
acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS). The …
Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database
J Charan, S Dutta, R Kaur, P Bhardwaj… - Expert opinion on …, 2021 - Taylor & Francis
Background Elevated inflammatory cytokines in Coronavirus disease 2019 (COVID‐19)
affect the lungs leading to pneumonitis with a poor prognosis. Tocilizumab, a type of …
affect the lungs leading to pneumonitis with a poor prognosis. Tocilizumab, a type of …